ASK-120067
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- ASK-120067
- Molecular weight
- 546.08
- Structure (SMILES)
- C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccc4ccccc4c3)n2)c(OC)cc1N(C)CCN(C)C
- ask 120067
- Ask-120067
- ask120067
- Ask120067
- ASK120067
- CAS registry numbers
- 1934259-00-3
- ChEMBL ID
- CHEMBL6068536
- InChIKey
- QHPVTCLSVVUPOF-UHFFFAOYSA-N
- PubChem compound IDs
- 121371196
- FDA ingredient codes (UNII)
- PRJ2UA27T7
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- limertinib
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
- Action type
- Inhibitor
- Target
- epidermal growth factor receptor
- Gene symbol
- epidermal growth factor receptor
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- epidermal growth factor receptor
- Gene symbol
- EGFR
- Protein identifier
- P00533
- Median affinity
- 8.22
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- epidermal growth factor receptor
- Gene symbol
- EGFR
- Protein identifier
- P00533
- Median affinity
- 9.3
- Affinity units
- pIC50
Investigated indications
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0056806
- Highest recorded phase
- 2
- NCT03502850
- NCT04143607
- NCT04360915
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 3
- Polar surface area
- 94.65
- Calculated partition coefficient (ALogP)
- 5.9
- Calculated partition coefficient (XLogP)
- 5.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 11
- Heavy atoms
- 39
- Molecular formula
- C29H32ClN7O2
- Monoisotopic mass
- 545.2306010
- Natural product
- No
Related records
Trials (5)
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
- Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects
- Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
In development for (1)
- Non-small cell lung carcinoma Phase 3